Deucravacitinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Rosacea. According to GlobalData, Phase II drugs for Rosacea have a 38% phase transition success ...
Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. ACU-D1 is under development for the treatment of severe acne rosacea ...